Literature DB >> 21900401

ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

Bin Guan1, Tian-Li Wang, Ie-Ming Shih.   

Abstract

ARID1A (BAF250A) promotes the formation of SWI/SNF chromatin remodeling complexes containing BRG1 or BRM. It has emerged as a candidate tumor suppressor based on its frequent mutations in ovarian clear cell and endometrioid cancers and in uterine endometrioid carcinomas. Here, we report that restoring wild-type ARID1A expression in ovarian cancer cells that harbor ARID1A mutations is sufficient to suppress cell proliferation and tumor growth in mice, whereas RNA interference-mediated silencing of ARID1A in nontransformed epithelial cells is sufficient to enhance cellular proliferation and tumorigenicity. Gene expression analysis identified several downstream targets of ARID1A including CDKN1A and SMAD3, which are well-known p53 target genes. In support of the likelihood that p53 mediates the effects of ARID1A on these genes, we showed that p53 was required and sufficient for their regulation by ARID1A. Furthermore, we showed that CDKN1A (encoding p21) acted in part to mediate growth suppression by ARID1A. Finally, we obtained evidence that the ARID1A/BRG1 complex interacted directly with p53 and that mutations in the ARID1A and TP53 genes were mutually exclusive in tumor specimens examined. Our results provide functional evidence in support of the hypothesis that ARID1A is a bona fide tumor suppressor that collaborates with p53 to regulate CDKN1A and SMAD3 transcription and tumor growth in gynecologic cancers. 2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900401      PMCID: PMC3206175          DOI: 10.1158/0008-5472.CAN-11-1562

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  The SWI/SNF complex and cancer.

Authors:  D Reisman; S Glaros; E A Thompson
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

2.  Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Authors:  Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

Review 3.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

4.  Genomic and functional evidence for an ARID1A tumor suppressor role.

Authors:  Jianmin Huang; Yan-Ling Zhao; Yu Li; Jonathan A Fletcher; Sheng Xiao
Journal:  Genes Chromosomes Cancer       Date:  2007-08       Impact factor: 5.006

Review 5.  Endometrial carcinoma.

Authors:  Antonio Di Cristofano; Lora Hedrick Ellenson
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

6.  The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1.

Authors:  Jim Jinn-Chyuan Sheu; Jung Hye Choi; Isil Yildiz; Fuu-Jen Tsai; Yosef Shaul; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

7.  BAF60a interacts with p53 to recruit the SWI/SNF complex.

Authors:  Jaehak Oh; Dong H Sohn; Myunggon Ko; Heekyoung Chung; Sung H Jeon; Rho H Seong
Journal:  J Biol Chem       Date:  2008-02-26       Impact factor: 5.157

8.  Identification of GRO1 as a critical determinant for mutant p53 gain of function.

Authors:  Wensheng Yan; Xinbin Chen
Journal:  J Biol Chem       Date:  2009-03-03       Impact factor: 5.157

9.  Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer.

Authors:  Jung Hye Choi; Jim Jinn-Chyuan Sheu; Bin Guan; Natini Jinawath; Paul Markowski; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

10.  ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a.

Authors:  Xiaolin Gao; Peri Tate; Ping Hu; Robert Tjian; William C Skarnes; Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-30       Impact factor: 11.205

View more
  190 in total

1.  Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.

Authors:  Yuji Matsuo; Hironori Tashiro; Hiroyuki Yanai; Takuya Moriya; Hidetaka Katabuchi
Journal:  Med Mol Morphol       Date:  2014-11-15       Impact factor: 2.309

2.  Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.

Authors:  Yali Zhai; Rork Kuick; Courtney Tipton; Rong Wu; Michael Sessine; Zhong Wang; Suzanne J Baker; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2015-09-15       Impact factor: 7.996

Review 3.  Mechanisms of epigenetic deregulation in lymphoid neoplasms.

Authors:  Yanwen Jiang; Katerina Hatzi; Rita Shaknovich
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

Review 4.  Emerging signaling pathways in hepatocellular carcinoma.

Authors:  Agrin Moeini; Helena Cornellà; Augusto Villanueva
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 5.  SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.

Authors:  Takeshi Fukumoto; Elizabeth Magno; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2018-07-23       Impact factor: 5.852

Review 6.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

7.  Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.

Authors:  Bin Guan; Min Gao; Chen-Hsuan Wu; Tian-Li Wang; Ie-Ming Shih
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

8.  ARID1A: a potential prognostic factor for breast cancer.

Authors:  Jing Zhao; Caigang Liu; Zuowei Zhao
Journal:  Tumour Biol       Date:  2014-01-16

9.  Functional redundancy of the Notch pathway in ovarian cancer cell lines.

Authors:  Fernanda Silva; Ana Félix; Jacinta Serpa
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

10.  Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.

Authors:  Yohan Suryo Rahmanto; Jin-Gyoung Jung; Ren-Chin Wu; Yusuke Kobayashi; Christopher M Heaphy; Alan K Meeker; Tian-Li Wang; Ie-Ming Shih
Journal:  J Biol Chem       Date:  2016-03-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.